Cladribine has been an unmitigated disaster. It was rejected by the EU in Sep 2010 (#msg-54812455). In the US, the writing was on the wall when the FDA issued a CRL in Mar 2011 after failing to evaluate the NDA during the allotted time despite its having a priority review designation (#msg-57103405).
One fewer competitor for Teva, MNTA, NVS, and BIIB to worry about.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.